Image
ECRIN Covid-19

Fast track procedure for COVID 19 clinical trials

Join forces worldwide to find a cure, a vaccine, and sharing research data

This webpage is no longer updated.

Most of the European countries have put in place accelerated procedures (“Fast track” procedure) for the evaluation and authorization of clinical trials related to the management of the pandemic COVID-19. In many countries the regulatory authorities have issued official guidelines for the accelerated procedure. Some of them cover also the ethical review process by the Ethics committee. In case such guidelines are not available/not being proposed, the authorities made a sort of formal statement that they consider the clinical trials on Covid-19 as a top priority. We have collected information from 16 Countries:

 

Belgium

Belgium

Addendum to the Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic), Federal Agency for Medicines and Health Products Eurostation, 25/03/2020.

 

Czech Republic

Czech Republic

No Fast track procedure publically available.

 

Denmark

Denmark

No Fast track procedure publically available

Statement from Danish Medicines agency: they prioritize all requests regarding COVID-19
Extraordinary measures for clinical trials due to COVID-19, Danish Medicines agency, 13/03/2020, updated 02/04/2020

 

France

France

Application for an initial authorization for COVID-19 related clinical trial, ANSM, First published 03/20/2020, last update 11/02/2022

 

Italy

Italy

Notice: Clinical trials’ management in Italy during the COVID-19 (coronavirus disease 19) emergency, AIFA, published on 12/03/2020, last update: Version 2 of 7/04/2020

Related topics
Circolare sulle procedure semplificate per gli studi gli usi compassionevoli per l'emergenza da COVID-19, AIFA

 

Ireland

Ireland

Ireland’s Health Products Regulatory Authority (HPRA), Department of Health, National Office for Research Ethics Committees and Health Research Declaration Committee have agreed on an expedited review process for human trials related to COVID-19. A dedicated COVID-19 national research ethics committee (NREC-COV19) has been established.

Guidance on the Management of Clinical Trials during COVID-19, HPRA, updated on 02/04/2020 (version 5.0)

COVID-19 Related Human Research – Expedited Regulatory and Ethical Review

 

Portugal

Portugal

COVID-19: Exceptional measures for conduct clincal trial during the COVID 19 (Coronavirus) pandemic, INFARMED, version 2 15/04/2020

Related topics
Informação CEIC sobre Ensaios Clínicos ou Estudos de intervenção com DM face à conjetura atual da Covid-19, National ethics committee for clinical research, version 31/03/2020, updated 03/04/2020

 

Slovakia

Slovakia

USMERNENIE ŠÚKL KU KLINICKÝM SKÚŠANIAM NA SLOVENSKU POČAS MIMORIADNEJ SITUÁCIE COVID-19, State Institute for Drug Control (SIDC), version 1 02/04/2020

 

Spain

Spain

No Fast track procedure publically available

Statement from the AEMPS : they prioritize all requests regarding COVID-19
Medidas adoptadas para facilitar la gestión de las autorizaciones y modificaciones de medicamentos de uso humano considerados esenciales durante la crisis de COVID-19, AEMPS, version 20/04/2020

United Kingdom

United Kingdom

Clinical trials applications for Coronavirus (COVID-19), MHRA, 19/03/2020

Related topics
Managing-clinical-trials-during-coronavirus-covid-19, MHRA, Last updated 22/04/2020

 

European Network of Research Ethics Committees 

European Network of Research Ethics Committees

Position of the European Network of Research Ethics Committees (EUREC) on the Responsibility of Research Ethics Committees during the COVID-19 Pandemic:

RECs should give clear priority to the assessment of submitted studies that are linked to the prevention or treatment of COVID-19 […]”, EUREC Board, 27/04/2020

 

 

Back to the Covid-19 clinical research pages.

Legal disclaimer for the COVID-19 clinical research pages.